• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

黏菌素与美罗培南或替加环素联合应用对耐碳青霉烯类细菌的体外协同作用

In Vitro Synergy of Colistin in Combination with Meropenem or Tigecycline against Carbapenem-Resistant .

作者信息

Abdul-Mutakabbir Jacinda C, Yim Juwon, Nguyen Logan, Maassen Philip T, Stamper Kyle, Shiekh Zain, Kebriaei Razieh, Shields Ryan K, Castanheira Mariana, Kaye Keith S, Rybak Michael J

机构信息

Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48202, USA.

Division of Infectious Diseases, University of Pittsburgh Medical School, Pittsburgh, PA 15213, USA.

出版信息

Antibiotics (Basel). 2021 Jul 20;10(7):880. doi: 10.3390/antibiotics10070880.

DOI:10.3390/antibiotics10070880
PMID:34356801
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8300792/
Abstract

is currently classified as one of six pathogens that contribute to increased patient mortality. Thus, exploratory studies navigating alternative treatment strategies are of supreme interest. Herein, we completed minimum inhibitory concentration (MIC) testing, and time-kill analyses (TKA) on 50 carbapenem-resistant isolates including 28 colistin-resistant isolates. Upon testing of MEM or TGC in the presence of sub-inhibitory COL against the 50 isolates, there was a median 2-fold reduction in MEM and TGC MICs. In the TKAs, the COL+MEM combination was synergistic in 45 (90%) isolates and bactericidal in 43 (86%) isolates at 24 hours, whereas the COL+TGC combination TKAs demonstrated synergy in 32 (64%) isolates and bactericidal activity was shown in 28 (56%) isolates. Additionally, sulbactam (SUL) and TGC were added to the COL+MEM dual therapy regimen to assess the possible utility of a triple therapy regimen against five non-responsive isolates. The COL+MEM+SUL and COL+MEM+TGC regimens effectively restored synergy in (5/5) 100% of the isolates. The results of this study demonstrate the potential utility of COL combinations in the treatment of carbapenem-resistant isolates.

摘要

目前被归类为导致患者死亡率增加的六种病原体之一。因此,探索替代治疗策略的研究极具意义。在此,我们对50株耐碳青霉烯类菌株(包括28株耐黏菌素菌株)进行了最低抑菌浓度(MIC)测试和时间杀菌分析(TKA)。在用亚抑菌浓度的黏菌素(COL)存在的情况下对50株菌株测试美罗培南(MEM)或替加环素(TGC)时,MEM和TGC的MIC中位数降低了2倍。在TKA中,COL+MEM组合在45株(90%)菌株中具有协同作用,在24小时时对43株(86%)菌株具有杀菌作用,而COL+TGC组合的TKA在32株(64%)菌株中显示出协同作用,在28株(56%)菌株中显示出杀菌活性。此外,将舒巴坦(SUL)和TGC添加到COL+MEM联合治疗方案中,以评估三联治疗方案对五株无反应菌株的可能效用。COL+MEM+SUL和COL+MEM+TGC方案在100%(5/5)的菌株中有效恢复了协同作用。本研究结果证明了COL联合用药在治疗耐碳青霉烯类菌株方面的潜在效用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77b1/8300792/b8c6f0862fba/antibiotics-10-00880-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77b1/8300792/20ef2f6637ea/antibiotics-10-00880-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77b1/8300792/b8c6f0862fba/antibiotics-10-00880-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77b1/8300792/20ef2f6637ea/antibiotics-10-00880-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77b1/8300792/b8c6f0862fba/antibiotics-10-00880-g002.jpg

相似文献

1
In Vitro Synergy of Colistin in Combination with Meropenem or Tigecycline against Carbapenem-Resistant .黏菌素与美罗培南或替加环素联合应用对耐碳青霉烯类细菌的体外协同作用
Antibiotics (Basel). 2021 Jul 20;10(7):880. doi: 10.3390/antibiotics10070880.
2
Investigating the in vitro synergistic activities of several antibiotic combinationsagainst carbapenem-resistant Acinetobacter baumannii isolates.研究几种抗生素组合对耐碳青霉烯鲍曼不动杆菌分离株的体外协同活性。
Turk J Med Sci. 2016 Apr 19;46(3):892-6. doi: 10.3906/sag-1408-14.
3
Antimicrobial effects of varied combinations of meropenem, sulbactam, and colistin on a multidrug-resistant Acinetobacter baumannii isolate that caused meningitis and bacteremia.美罗培南、舒巴坦和黏菌素不同组合对一株引起脑膜炎和菌血症的多重耐药鲍曼不动杆菌分离株的抗菌作用。
Microb Drug Resist. 2008 Sep;14(3):233-7. doi: 10.1089/mdr.2008.0840.
4
In vitro and in vivo Effect of Antimicrobial Agent Combinations Against Carbapenem-Resistant with Different Resistance Mechanisms in China.抗菌药物联合应用对中国不同耐药机制碳青霉烯类耐药菌的体外和体内作用
Infect Drug Resist. 2021 Mar 5;14:917-928. doi: 10.2147/IDR.S292431. eCollection 2021.
5
Exploring Synergistic Combinations in Extended and Pan-Drug Resistant (XDR and PDR) Whole Genome Sequenced .探索广泛耐药和泛耐药(XDR和PDR)全基因组测序中的协同组合
Microorganisms. 2023 May 26;11(6):1409. doi: 10.3390/microorganisms11061409.
6
In-Vitro Evaluation of Different Antimicrobial Combinations with and without Colistin Against Carbapenem-Resistant .体外评估含或不含黏菌素的不同抗菌药物组合对碳青霉烯类耐药肠杆菌科细菌的效果
Molecules. 2019 Mar 3;24(5):886. doi: 10.3390/molecules24050886.
7
Semi-mechanistic PK/PD modelling of meropenem and sulbactam combination against carbapenem-resistant strains of Acinetobacter baumannii.美罗培南-舒巴坦合剂对耐碳青霉烯鲍曼不动杆菌的半机械性 PK/PD 模型研究。
Eur J Clin Microbiol Infect Dis. 2021 Sep;40(9):1943-1952. doi: 10.1007/s10096-021-04252-z. Epub 2021 Apr 22.
8
Tigecycline in combination with other antibiotics against clinical isolates of carbapenem-resistant Klebsiella pneumoniae in vitro.替加环素与其他抗生素联合用于体外抗耐碳青霉烯类肺炎克雷伯菌临床分离株的研究
Ann Palliat Med. 2019 Nov;8(5):622-631. doi: 10.21037/apm.2019.09.11. Epub 2019 Oct 23.
9
[In vitro synergistic activity of sulbactam in combination with imipenem, meropenem and cefoperazone against carbapenem-resistant Acinetobacter baumannii isolates].舒巴坦与亚胺培南、美罗培南和头孢哌酮联合对耐碳青霉烯类鲍曼不动杆菌分离株的体外协同活性
Mikrobiyol Bul. 2014 Apr;48(2):311-5. doi: 10.5578/mb.7104.
10
Antibiotics Combinations and Chitosan Nanoparticles for Combating Multidrug Resistance .用于对抗多重耐药性的抗生素组合与壳聚糖纳米颗粒
Infect Drug Resist. 2021 Aug 20;14:3327-3339. doi: 10.2147/IDR.S328788. eCollection 2021.

引用本文的文献

1
In Vitro Evaluation of Antimicrobial Synergy Against Multidrug-Resistant Gram-Negative Paediatric Bloodstream Pathogens in South Africa.南非针对多重耐药革兰氏阴性儿科血流病原体的抗菌协同作用的体外评估
Antibiotics (Basel). 2025 Jun 20;14(7):630. doi: 10.3390/antibiotics14070630.
2
Salvage Therapy Against Infections of MDR Achieved by Synergistic Effect of Colistin-Containing Therapies-Preliminary Study.含黏菌素疗法协同效应实现的耐多药感染挽救治疗——初步研究
Microorganisms. 2025 May 25;13(6):1206. doi: 10.3390/microorganisms13061206.
3
Mortality and clinical outcomes of colistin versus colistin-based combination therapy for infections caused by Multidrug-resistant Acinetobacter baumannii in critically ill patients.

本文引用的文献

1
Efficacy of tigecycline monotherapy versus combination therapy with other antimicrobials against carbapenem-resistant Acinetobacter baumannii sequence type 2 in Heilongjiang Province.替加环素单药治疗与其他抗菌药物联合治疗对黑龙江省耐碳青霉烯类鲍曼不动杆菌序列型2的疗效
Ann Palliat Med. 2019 Nov;8(5):651-659. doi: 10.21037/apm.2019.11.06.
2
International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP).多黏菌素优化使用国际共识指南:获得美国临床药师协会(ACCP)、欧洲临床微生物学和传染病学会(ESCMID)、美国感染病学会(IDSA)、国际抗感染药理学会(ISAP)、重症医学学会(SCCM)和感染病药师学会(SIDP)认可。
Pharmacotherapy. 2019 Jan;39(1):10-39. doi: 10.1002/phar.2209.
多黏菌素与基于多黏菌素的联合治疗对重症患者耐多药鲍曼不动杆菌感染的死亡率及临床结局
BMC Infect Dis. 2025 Mar 26;25(1):416. doi: 10.1186/s12879-025-10781-1.
4
Whether to continue combining carbapenems to treat carbapenem-resistant Acinetobacter baumannii nosocomial pneumonia in critically ill patients: a retrospective efficacy and safety analysis.是否继续联合使用碳青霉烯类药物治疗重症患者的耐碳青霉烯鲍曼不动杆菌医院获得性肺炎:一项回顾性疗效与安全性分析。
Eur J Clin Microbiol Infect Dis. 2025 Apr;44(4):973-983. doi: 10.1007/s10096-025-05063-2. Epub 2025 Feb 15.
5
Colistin Resistance Mechanism and Management Strategies of Colistin-Resistant Infections.黏菌素耐药机制及耐黏菌素感染的管理策略
Pathogens. 2024 Nov 28;13(12):1049. doi: 10.3390/pathogens13121049.
6
Overcoming (X)-harboring tigecycline resistance: a study on the efficacy of tigecycline-apramycin combinations.克服携带(X)的替加环素耐药性:替加环素-阿普拉霉素联合用药疗效研究
Front Microbiol. 2024 Dec 23;15:1502558. doi: 10.3389/fmicb.2024.1502558. eCollection 2024.
7
In-vitro evaluation of different antimicrobial combinations with and without colistin against carbapenem-resistant Acinetobacter baumannii clinical isolates.体外评估不同抗菌药物组合(含或不含多黏菌素)对碳青霉烯类耐药鲍曼不动杆菌临床分离株的作用。
Eur J Med Res. 2024 Jun 16;29(1):331. doi: 10.1186/s40001-024-01885-6.
8
Successful Treatment of Carbapenem-Resistant Acinetobacter baumannii Meningitis With Sulbactam-Durlobactam.舒巴坦-多利培南成功治疗耐碳青霉烯鲍曼不动杆菌脑膜炎
Clin Infect Dis. 2024 Oct 15;79(4):819-825. doi: 10.1093/cid/ciae210.
9
Determining Susceptibility and Potential Mediators of Resistance for the Novel Polymyxin Derivative, SPR206, in .确定新型多粘菌素衍生物SPR206在……中的敏感性及耐药性的潜在介导因素
Antibiotics (Basel). 2024 Jan 4;13(1):47. doi: 10.3390/antibiotics13010047.
10
Efficacy of Cefoperazone Sulbactam in Patients with Infections: A Systematic Review of the Literature.头孢哌酮舒巴坦治疗感染患者的疗效:文献系统评价
Antibiotics (Basel). 2023 Mar 15;12(3):582. doi: 10.3390/antibiotics12030582.
3
The Search for a Practical Method for Colistin Susceptibility Testing: Have We Found It by Going Back to the Future?寻找一种实用的多粘菌素药敏试验方法:我们是否通过回到未来找到了它?
J Clin Microbiol. 2019 Jan 30;57(2). doi: 10.1128/JCM.01608-18. Print 2019 Feb.
4
Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.多黏菌素单用与多黏菌素联合美罗培南治疗碳青霉烯类耐药革兰氏阴性菌引起的严重感染:一项开放标签、随机对照试验。
Lancet Infect Dis. 2018 Apr;18(4):391-400. doi: 10.1016/S1473-3099(18)30099-9. Epub 2018 Feb 16.
5
In vitro activity of colistin mono- and combination therapy against colistin-resistant , mechanism of resistance, and clinical outcomes of patients infected with colistin-resistant at a Thai university hospital.多黏菌素单药及联合治疗对耐多黏菌素菌的体外活性、耐药机制以及泰国一家大学医院耐多黏菌素菌感染患者的临床结局
Infect Drug Resist. 2017 Nov 20;10:437-443. doi: 10.2147/IDR.S148185. eCollection 2017.
6
Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes.多粘菌素:抗菌活性、药敏试验以及由质粒或染色体编码的耐药机制
Clin Microbiol Rev. 2017 Apr;30(2):557-596. doi: 10.1128/CMR.00064-16.
7
Carbapenem Breakpoints for Acinetobacter baumannii Group: Supporting Clinical Outcome Data from Patients with Bacteremia.鲍曼不动杆菌属的碳青霉烯类药物敏感性断点:来自菌血症患者的支持性临床结果数据
PLoS One. 2016 Sep 19;11(9):e0163271. doi: 10.1371/journal.pone.0163271. eCollection 2016.
8
Meta-analysis of colistin for the treatment of Acinetobacter baumannii infection.黏菌素治疗鲍曼不动杆菌感染的荟萃分析。
Sci Rep. 2015 Nov 24;5:17091. doi: 10.1038/srep17091.
9
Secular trends in Acinetobacter baumannii resistance in respiratory and blood stream specimens in the United States, 2003 to 2012: A survey study.2003年至2012年美国呼吸道和血流标本中鲍曼不动杆菌耐药性的长期趋势:一项调查研究。
J Hosp Med. 2016 Jan;11(1):21-6. doi: 10.1002/jhm.2477. Epub 2015 Sep 9.
10
Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance.耐黏菌素鲍曼不动杆菌:超越碳青霉烯类耐药性
Clin Infect Dis. 2015 May 1;60(9):1295-303. doi: 10.1093/cid/civ048. Epub 2015 Jan 28.